Extended Surgical Resection in Stage III Non-Small Cell Lung Cancer

被引:0
作者
Hillinger, Sven [1 ]
Weder, Walter [1 ]
机构
[1] Univ Zurich Hosp, Div Thorac Surg, CH-8091 Zurich, Switzerland
来源
CONTROVERSIES IN TREATMENT OF LUNG CANCER | 2010年 / 42卷
关键词
EN-BLOC RESECTION; CONCURRENT CHEMOTHERAPY; INDUCTION CHEMOTHERAPY; RADIOTHERAPY; SURGERY; CHEMORADIATION; SURVIVAL; OUTCOMES;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Stage III includes a large variety of clinical situations from chest wall invasion together with intralobar lymph node metastasis to any size of a lung cancer in combination with mediastinal lymph node involvement (N2/N3). Furthermore, the prognosis of patients with lymph node metastasis depends largely on the extent of the disease, which may range from micro-metastasis occasionally found during surgery to bulky and/or multilevel involvement of the mediastinum or extracapsular infiltration. Not surprising the optimal treatment including the role of surgery for stage IIIA (N2) and stage IIIB (T4/N3) non-small cell lung cancer is discussed controversially. Adequate analysis of the clinical stage is key to select the best treatment. In general, patients benefit from surgery, when a radical resection can be achieved with a low morbidity and mortality. A multidisciplinary approach is indicated in most patients, which present with stage III disease at diagnosis. Preferentially patients should be treated in study protocols whenever they are available. Radical surgery including chest wall resection may result in a 5-year survival rate of up to 50% in T3N1 disease. Adjuvant chemotherapy is recommended and radiotherapy is reserved for cases with unclear resection margins. Clinical trials of preoperatively proven N2 patients could show a better outcome when downstaging is achieved after neoadjuvant chemo- or chemoradiotherapy prior to surgery. Patients who may need a pneumonectomy should be selected with caution since some centers experience a high perioperative mortality rate. If unforeseen N2 disease is found during surgery, an adjuvant therapy is recommended. Patients with T4 tumors (infiltration of great vessels, trachea, esophagus, vertebral bodies, etc.) show an increasing 5-year survival from 15 to 35% after radical resection with acceptable perioperative mortality if treated in experienced centers. In stage III non-small cell lung cancer, surgery should be performed within a multimodality approach. Surgery should be recommended when resection is radical including systematic lymph node dissection and mortality and morbidity are low. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:115 / 121
页数:7
相关论文
共 23 条
[1]  
Albain K S, 1997, Oncology (Williston Park), V11, P51
[2]  
Albain KS, 2005, J CLIN ONCOL, V23, p624S
[3]   Survival of patients with resected N2 non-small-cell lung cancer: Evidence for a subclassification and implications [J].
Andre, F ;
Grunenwald, D ;
Pignon, JP ;
Dujon, A ;
Pujol, JL ;
Brichon, PY ;
Brouchet, L ;
Quoix, E ;
Westeel, V ;
Le Chevalier, T .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2981-2989
[4]   Mediastinal lymph node clearance after docetaxel-cisplatin Neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer:: A multicenter phase II trial [J].
Betticher, DC ;
Schmitz, SFH ;
Tötsch, M ;
Hansen, E ;
Joss, C ;
von Briel, C ;
Schmid, RA ;
Pless, M ;
Habicht, J ;
Roth, AD ;
Spiliopoulos, A ;
Stahel, R ;
Weder, W ;
Stupp, R ;
Egli, F ;
Furrer, M ;
Honegger, H ;
Wernli, M ;
Cerny, T ;
Ris, HB .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (09) :1752-1759
[5]   Results of en bloc resection for bronchogenic carcinoma with chest wall invasion [J].
Burkhart, HM ;
Allen, MS ;
Nichols, FC ;
Deschamps, C ;
Miller, DL ;
Trastek, VF ;
Pairolero, PC .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (04) :670-675
[6]   Pulmonary resection after concurrent chemotherapy and high dose (60 Gy) radiation for non-small cell lung cancer is safe and may provide increased survival [J].
Cerfolio, Robert James ;
Bryant, Ayesha S. ;
Jones, Virginia L. ;
Cerfolio, Robert Michael .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2009, 35 (04) :718-723
[7]   Trends in the operative management and outcomes of T4 lung cancer [J].
Farjah, Farhood ;
Wood, Douglas E. ;
Varghese, Thomas K., Jr. ;
Symons, Rebecca Gaston ;
Flum, David R. .
ANNALS OF THORACIC SURGERY, 2008, 86 (02) :368-375
[8]   Radical en bloc resection for lung cancer invading the spine [J].
Grunenwald, DH ;
Mazel, C ;
Girard, P ;
Veronesi, G ;
Spaggiari, L ;
Gossot, D ;
Debrosse, D ;
Caliandro, R ;
Le Guillou, JL ;
Le Chevalier, T .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2002, 123 (02) :271-279
[9]   Benefit of surgery after chemoradiotherapy in stage IIIB (T4 and/or N3) non-small cell lung cancer [J].
Grunenwald, DH ;
André, F ;
Le Péchoux, C ;
Girard, P ;
Lamer, C ;
Laplanche, A ;
Tarayre, M ;
Arriagada, R ;
Le Chevalier, T .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2001, 122 (04) :796-802
[10]  
Grunenwald DH, 2000, SEMIN SURG ONCOL, V18, P137, DOI 10.1002/(SICI)1098-2388(200003)18:2<137::AID-SSU7>3.0.CO